Option chain shows key data for Indaptus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Indaptus Therapeutics.

Indaptus Therapeutics (NASDAQ:INDP) Stock, Option Chain

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CRML

CSTL

CTKB

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INDP

INSG

IONQ

IRWD

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OCEA

OKTA

ORIC

PSTG

PZZA

QURE

RNLX

RVNC

SCTL

SDGR

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Shares of  Butterfly Network, Inc.  (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

Envoy Medical, Inc. - Class A Common Stock

COCH

ESGL

VYGR

Shares of  Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and 

Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket

ACXP

AFIB

AIRE

AMWL

ASTR

BANL

BEST

BGNE

BHIL

CAUD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CLDX

CNFR

CRBU

CREV

CTNT

DBGI

DISH

DOGZ

FRPT

GDEV

Hollsys Automation Technologies INTERNATIONAL

HOLI

KXIN

LICY

LIFW

MLTX

NSSC

PRFX

PRME

PROC

RYAAY

SATS

TGLS

VERB

WHLR

Gainers


	Carbon Revolution Public Limited  (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.


Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

Guidance

Gen Sees Q4 2025 Revenue $990M-$1.005B Vs $995.19M Estimate

WIIM

Gen Digital shares are trading lower. The company reported Q3 financial results.

DECK

Deckers Outdoor shares are trading lower. The company reported Q3 financial results.

<p>The following details guidance for the third quarter of fiscal 2025 ending in March:</p>
<ul>
<li>GAAP gross margin is expected to be in a range of 60.6% +/- 1.0%</li>
<li>Non-GAAP gross margin is expected to be in a range of 62.0% +/- 1.0%</li>
<li>GAAP diluted EPS is expected to be in a range of $7.77 +/- $0.60</li>
</ul>


KLAC

KLA Expects Q3 Total Revenues Of $3.0B +/- $150M (Est $2.887B); Adj EPS Of $8.05 +/- $0.60 (Est $5.26)

<p>PCB Bancorp (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>), the holding company of PCB Bank, announced that on January 29, 2025, its Board of Directors declared a quarterly cash dividend of $0.20 per common share. The dividend will be paid on or about February 21, 2025, to shareholders of record as of the close of business on February 14, 2025.</p>


Dividends

PCB Bancorp Declares Increased Quarterly Cash Dividend From $0.18 To $0.20 Per Share

KLA Corp shares are trading higher following better-than-expected Q2 financial results.

<p>PCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>) reported quarterly earnings of $0.46 per share which met the analyst consensus estimate. This is a 12.2 percent increase over earnings of $0.41 per share from the same period last year.</p>


Earnings

PCB Bancorp Q4 EPS $0.46, Inline

<p>Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) affirms FY2025 GAAP EPS guidance from $5.25 to $5.25 vs $5.24 analyst estimate..</p>


TBBK

Bancorp Affirms FY2025 GAAP EPS Guidance from $5.25 to $5.25 vs $5.24 Est

<p><strong>AppFolio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>AppFolio missed estimated earnings by -2.0%, reporting an EPS of $0.92 versus an estimate of $0.94.</p>
<p>Revenue was up $31.83 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.26, leading to a 11.0% increase share price change the next day.</p>
<p>Here's a look at AppFolio's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.03</td>
<td>0.96</td>
<td>0.89</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.29</td>
<td>1.12</td>
<td>1.05</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>199.10M</td>
<td>190.57M</td>
<td>178.69M</td>
<td>162.71M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>205.73M</td>
<td>197.38M</td>
<td>187.43M</td>
<td>171.83M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for AppFolio <a href="https://www.benzinga.com/quote/APPF/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


APPF

AppFolio Earnings Review: Q4 Summary

<p>Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) reported quarterly earnings of $1.91 per share which beat the analyst consensus estimate of $1.67 by 14.37 percent. This is a 3.8 percent increase over earnings of $1.84 per share from the same period last year.  The company reported quarterly sales of $189.81 million which beat the analyst consensus estimate of $189.47 million by 0.18 percent.  This is a 6.40 percent increase over sales of $178.40 million the same period last year.</p>


Earnings Beats

Standex International Q2 Adj $1.91 Beats $1.67 Estimate, Sales $189.81M Beat $189.47M Estimate

<p><strong>Olin</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Olin beat estimated earnings by 325.0%, reporting an EPS of $0.09 versus an estimate of $-0.04.</p>
<p>Revenue was up $56.40 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company missed on EPS by $0.25, resulting in a 8.0% drop change in the share price the following day.</p>
<p>Here's a look at Olin's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.04</td>
<td>0.70</td>
<td>0.38</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.21</td>
<td>0.62</td>
<td>0.40</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.57B</td>
<td>1.71B</td>
<td>1.65B</td>
<td>1.52B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.59B</td>
<td>1.64B</td>
<td>1.64B</td>
<td>1.61B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Olin <a href="https://www.benzinga.com/quote/OLN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Olin Earnings Report: Q4 Overview

TEAM

Atlassian shares are trading higher after the company reported better-than-expected Q2 financial results.

<p>The earnings results for <strong>First Business Finl Servs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:00 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>First Business Finl Servs beat estimated earnings by 13.0%, reporting an EPS of $1.43 versus an estimate of $1.26.</p>
<p>Revenue was up $4.52 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.05 which was followed by a 4.0% drop in the share price the next day.</p>
<p>Here's a look at First Business Finl Servs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.19</td>
<td>1.09</td>
<td>1.12</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.24</td>
<td>1.23</td>
<td>1.04</td>
<td>1.15</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>38.77M</td>
<td>37.25M</td>
<td>37.73M</td>
<td>37.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>38.07M</td>
<td>37.97M</td>
<td>36.28M</td>
<td>36.63M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for First Business Finl Servs <a href="https://www.benzinga.com/quote/FBIZ/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FBIZ

First Business Finl Servs Earnings Review: Q4 Summary

<p>LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) reported quarterly earnings of $4.25 per share which beat the analyst consensus estimate of $3.94 by 7.87 percent. This is a 21.08 percent increase over earnings of $3.51 per share from the same period last year.  The company reported quarterly sales of $3.51 billion which beat the analyst consensus estimate of $3.31 billion by 6.02 percent.  This is a 32.83 percent increase over sales of $2.64 billion the same period last year.</p>


LPLA

LPL Finl Hldgs Q4 Adj EPS $4.25 Beats $3.94 Estimate, Sales $3.51B Beat $3.31B Estimate

<p>The Q2 earnings report for <strong>Atlassian</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) was released on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Atlassian beat estimated earnings by 26.0%, reporting an EPS of $0.96 versus an estimate of $0.76.</p>
<p>Revenue was up $226.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>Last quarter the company beat on EPS by $0.13 which was followed by a 19.0% increase in the share price the next day.</p>
<p>Here's a look at Atlassian's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.64</td>
<td>0.61</td>
<td>0.62</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.77</td>
<td>0.66</td>
<td>0.89</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.15B</td>
<td>1.13B</td>
<td>1.10B</td>
<td>1.02B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.19B</td>
<td>1.13B</td>
<td>1.19B</td>
<td>1.06B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Atlassian <a href="https://www.benzinga.com/quote/TEAM/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Atlassian Q2

<p>Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.13 by 1.77 percent. This is a 21.05 percent increase over earnings of $0.95 per share from the same period last year.  The company reported quarterly sales of $94.30 million which missed the analyst consensus estimate of $96.76 million by 2.55 percent.  This is a 2.32 percent increase over sales of $92.16 million the same period last year.</p>


Earnings Misses

Bancorp Q4 EPS $1.15 Beats $1.13 Estimate, Sales $94.30M Miss $96.76M Estimate

<p><strong>Gen Digital</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) reported its Q3 earnings results on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Gen Digital beat estimated earnings by 2.0%, reporting an EPS of $0.56 versus an estimate of $0.55.</p>
<p>Revenue was up $35.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous quarter, the company missed on EPS by $0.0, resulting in a 8.0% increase change in the share price the following day.</p>
<p>Here's a look at Gen Digital's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.53</td>
<td>0.52</td>
<td>0.50</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.54</td>
<td>0.53</td>
<td>0.53</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>969.93M</td>
<td>965.06M</td>
<td>965.02M</td>
<td>956.20M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>974.00M</td>
<td>965.00M</td>
<td>967.00M</td>
<td>951.00M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Gen Digital management provided guidance for Q4 2025, expecting earnings between $0.57 and $0.59 per share.</p>
<p>To track all earnings releases for Gen Digital <a href="https://www.benzinga.com/quote/GEN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Gen Digital Q3 Earnings Assessment

<p><strong>Credit Acceptance</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) just disclosed its Q4 earnings on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Credit Acceptance beat estimated earnings by 28.000000000000004%, reporting an EPS of $10.17 versus an estimate of $7.93.</p>
<p>Revenue was up $74.30 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>Last quarter the company missed on EPS by $0.26 which was followed by a 8.0% drop in the share price the next day.</p>
<p>Here's a look at Credit Acceptance's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>9.05</td>
<td>8.91</td>
<td>8.35</td>
<td>5.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>8.79</td>
<td>10.29</td>
<td>9.28</td>
<td>10.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>545.89M</td>
<td>525.03M</td>
<td>455.76M</td>
<td>489.53M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>550.30M</td>
<td>538.20M</td>
<td>508.00M</td>
<td>491.60M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Credit Acceptance <a href="https://www.benzinga.com/quote/CACC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CACC

Earnings Breakdown: Credit Acceptance Q4

<p>Credit Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) reported quarterly earnings of $10.17 per share which beat the analyst consensus estimate of $7.93 by 28.25 percent. This is a 1.09 percent increase over earnings of $10.06 per share from the same period last year.  The company reported quarterly sales of $565.90 million which beat the analyst consensus estimate of $522.60 million by 8.29 percent.  This is a 15.11 percent increase over sales of $491.60 million the same period last year.</p>


Credit Acceptance Q4 Adj EPS $10.17 Beats $7.93 Estimate, Sales $565.90M Beat $522.60M Estimate

<p><strong>Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Bancorp beat estimated earnings by 2.0%, reporting an EPS of $1.15 versus an estimate of $1.13.</p>
<p>Revenue was up $2.14 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed on EPS by $0.08 which was followed by a 14.000000000000002% drop in the share price the next day.</p>
<p>Here's a look at Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.07</td>
<td>1.05</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.07</td>
<td>1.06</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>99.31M</td>
<td>96.41M</td>
<td>116.51M</td>
<td>90.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>93.73M</td>
<td>93.80M</td>
<td>94.42M</td>
<td>92.16M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Bancorp management provided guidance for FY 2025, expecting earnings between $5.25 and $5.25 per share.</p>
<p>To track all earnings releases for Bancorp <a href="https://www.benzinga.com/quote/TBBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Bancorp Q4

Press Releases

Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy

Health Care

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Financing

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Maxim Group

HC Wainwright & Co.

Comments

Indaptus Therapeutics

Indaptus Therapeutics (INDP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga